Drug intelligence / Profile preview

Bombyx batryticatus

Development stage: Unknown
Modality: Recombinant Proteins and Enzymes, Peptides
Administration: Oral

Overview

Bombyx batryticatus, also known as Jangcan, is a traditional Chinese medicine used for treating various conditions such as convulsions, epilepsy, cough, asthma, headaches, and purpura. It contains proteins, peptides, fatty acids, flavonoids, nucleosides, steroids, coumarin, and polysaccharides. Its extracts have shown pharmacological effects including anticonvulsant, antiepileptic, anticoagulant, antitumor, antibacterial, antifungal, antioxidant, and hypoglycemic activities. It is also studied for its potential as an immune potentiator in cancer vaccines.

Other names: Jangcan僵蠶

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)

Beyond the preview

Go deeper on Bombyx batryticatus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bombyx batryticatus.

Explore the full profile